Navigation

Ankylosing spondylitis - adalimumab, etanercept and infliximab

Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis

Status: History
Expected date of issue: May 2008
Process: MTA
Topic area:
 

NICE project team

Executive Lead: Andrew Dillon
Technical Lead: David Chandiwana
Communications manager: Kristin O'Leary.
Project manager: Eloise Saile
Assessment Group / Evidence Review Group: Liverpool Reviews & Implementation Group, University of Liverpool (LRiG)
Top


 

Provisional schedule

Consultation on draft scope by stakeholders: September 2004
Information meeting with consultees: 09 November 2005
Closing date for invited submissions / evidence submission: 25 January 2006
Final scope published: September 2005
1st appraisal committee meeting: 25 July 2006
2nd appraisal committee meeting: 22 November 2006
3rd appraisal committee meeting: 21 February 2007
4th appraisal committee meeting: 27 June 2007
5th appraisal committee meeting: 22 August 2007
Top


 

Consultees and commentators

Consultees Commentators (no right of appeal)

Manufacturers / Sponsors

  • Abbott Laboratories Ltd (adalimumab)
  • Schering-Plough Ltd (infliximab)
  • Wyeth Pharmaceuticals Ltd  (etanercept)

Patient / Carer Groups

  • Arthritis and Muscloskeletal Alliance
  • Arthritis Care
  • Back Care
  • National Ankylosing Spondylitis Society
  • Royal Association for Disability and Rehabilitation

Professional Groups

  • British Health Professionals in Rheumatology
  • British Orthopaedic Association
  • British Society for Rheumatology
  • British Society of Rehabilitation Medicine
  • Primary Care Rheumatology Society
  • Royal College of General Practitioners
  • Royal College of Nursing
  • Royal College of Ophthalmologists
  • Royal College of Physicians

Others

  • Chesterfield PCT
  • Department of Health
  • Solihull PCT
  • Welsh Assembly Government

General

  • British National Formulary
  • NHS Confederation
  • NHS Quality Improvement Scotland
  • Medicines and Healthcare products Regulatory Agency

Comparator Manufacturers

  • None

Assessment Team

  • Liverpool Reviews and Implementation Group, University of Liverpool
  • National Coordinating Centre for Health Technology Assessment

Associated Guideline Groups

  • None

Associated Public Health Groups

  • None

Research Groups

  • Arthritis Research Campaign

Top


 

Project history

Date Update
10 February 2004 Date of Information meeting for consultees added.
13 September 2004 Draft scope and provisional matrix of consultees and commentators published.
23 September 2004 Assessment group corrected.
28 September 2004 Technical lead identified.
24 January 2004 Technology Appraisal Project Manager changed.
10 June 2005 Schedule dates amended.
30 June 2005 Information meeting for consultees date changed.
5 August 2005 Appraisal status changed.
30 September 2005 Final scope, final matrix of consultees and commentators, and comments on draft scope and draft matrix of consultees and commentators published.
18 November 2005
25 July 2006
Final protocol added.

At the first Appraisal Committee meeting for this appraisal, the Committee requested some additional analysis of the cost effectiveness of adalimumab, etanercept and infliximab that may assist in making a fully informed decision. Consequently the timeline has been extended for this appraisal and these are reflected in the revised timetable provided above.
21 February 2007 After careful consideration, the Committee was not able to reach a conclusion on the cost effectiveness of adalimumab, etanercept and infliximab. After further discussion the Committee asked the Institute to commission further analysis to inform its decision.
Top


 

Key documents

This page was last updated: 30 March 2010

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.